A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

被引：29
|
作者：
Papadopoulos, Kyriakos P.
Ou, Sai-Hong Ignatius
Johnson, Melissa Lynne
Christensen, James
Velastegui, Karen
Potvin, Diane
Faltaos, Demiana
Chao, Richard C.
机构：
[1] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[2] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Mirati Therapeut Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS3161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3161
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Characteristics and treatment outcomes in advanced stage non-small cell lung cancer patients with KRAS G12C mutation
    Illini, Oliver
    Fabikan, Hannah
    Hochmair, Maximilian J.
    Weinlinger, Christoph
    Krenbek, Dagmar
    Brcic, Luka
    Setinek, Ulrike
    Terbuch, Angelika
    Absenger, Gudrun
    Konji, Selma
    Valipour, Arschang
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (19-20) : 727 - 728
  • [42] A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors
    Cho, Byoung Chul
    Lu, Shun
    Lee, Myung Ah
    Song, Zhengbo
    Park, John
    Lim, Sun Min
    Li, Ziming
    Zhao, Jun
    Richardson, Gary
    Zhang, Yanqiao
    Zhang, Jun
    Liu, Anwen
    Chen, Cheng
    Wang, Jia
    Lu, Jingtao
    Rui, Haopeng
    Chen, Qian
    Wang, Hui
    Zhang, Jing
    Chen, Zhi Jian
    Mok, Tony
    CANCER RESEARCH, 2024, 84 (07)
  • [43] Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC
    Zhang, J.
    Leventakos, K.
    Leal, T. A.
    Pennell, N.
    Barve, M.
    Paulson, A. S.
    Bazhenova, L.
    Johnson, M. L.
    Chao, R. C.
    Velastegui, K.
    Qian, C.
    Bleker, W.
    Spira, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1068 - S1069
  • [44] KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation
    Bekaii-Saab, Tanios S.
    Spira, Alexander I.
    Yaeger, Rona
    Buchschacher, Gary L.
    McRee, Autumn Jackson
    Sabari, Joshua K.
    Johnson, Melissa Lynne
    Barve, Minal A.
    Hafez, Navid
    Velastegui, Karen
    Christensen, James G.
    Kheoh, Thian
    Der-Torossian, Hirak
    Rybkin, Igor I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [45] Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
    Griesinger, F.
    Eberhardt, W.
    Hoffknecht, P.
    Metzenmacher, M.
    Wehler, T.
    Kokowski, K.
    Alt, J.
    Schuette, W.
    Jaenicke, M.
    Fleitz, A.
    Zacharias, S.
    Hipper, A.
    Buller, M.
    Weichert, W.
    Groschek, M.
    von der Heyde, E.
    Rauh, J.
    Dechow, T.
    Sebastian, M.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 135 - 135
  • [46] Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
    Griesinger, F.
    Eberhardt, W. E. E.
    Hoffknecht, P.
    Metzenmacher, M.
    Wehler, T.
    Kokowski, K.
    Alt, J.
    Schuette, W.
    Jaenicke, M.
    Fleitz, A.
    Zacharias, S.
    Hipper, A.
    Buller, M.
    Weichert, W.
    Groschek, M.
    von der Heyde, E.
    Rauh, J.
    Dechow, T.
    Sebastian, M.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S872 - S872
  • [47] 31507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
    Gadgeel, Shirish M.
    Miao, Jieling
    Riess, Jonathan W.
    Mack, Philip C.
    Gerstner, Gregory James
    Burns, Timothy F.
    Taj, Asma
    Akerley, Wallace L.
    Dragnev, Konstantin H.
    Moon, James
    Gandara, David R.
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [48] Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation
    Desai, Jayesh
    Han, Sae-Won
    Lee, Jong-Seok
    Shacham-Shmueli, Einat
    Massarelli, Erminia
    Cervantes, Andres
    Garralda, Elena
    Falcon, Alejandro
    Miller, Wilson H.
    Gort, Eelke
    Karasic, Thomas
    Siena, Salvatore
    Stec, Rafal
    Medina, Laura
    Paz-Arez, Luis
    Delmonte, Angelo
    Sacher, Adrian
    Prenen, Hans
    Forster, Martin
    Kim, Tae Won
    Krebs, Matthew G.
    Cosman, Rasha
    Choi, Yoonha
    Mandlekar, Sandhya
    Lin, Mark T.
    Yau, Kenneth K.
    Chang, Julie
    Royer-Joo, Stephanie
    Dharia, Neekesh V.
    Schutzman, Jennifer L.
    Patel, Manish
    CANCER RESEARCH, 2023, 83 (08)
  • [49] Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation
    Desai, J.
    Han, S-W.
    Forster, M. D.
    Kim, T. W.
    Alonso Casal, G.
    Shmueli, E. Shacham
    Bowyer, S. E.
    De Miguel, M. J.
    Gonzalez, A. Falcon
    Jones, R. H.
    Krebs, M. G.
    Miller, W. H.
    Paz-Ares, L.
    Lorusso, P.
    Sacher, A.
    Dharia, N.
    Lin, M. T.
    Schutzman, J. L.
    Shi, Z.
    Patel, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S701 - S702
  • [50] Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).
    Keating, Anne Therese
    Papadopoulos, Kyriakos P.
    Hloros, Eleni
    Spira, Alexander I.
    McKean, William Bennion
    Krivoshik, Andrew Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345